Table 3.
The information of studies detecting VEGF level in sputum, MPE, and EBC.
| Ref/First Authors | Ethnic | No. of cases | Character | Method (kits ) |
Kit's sensitivity | Biomarkers | Detecting time | Stage/ type |
Treatment /diagnosis |
|---|---|---|---|---|---|---|---|---|---|
| [80]Tony Mok | Asia Causasian |
303 | Protective Multicenter Randomized |
ELSIA(R&D Systems Minneapolis, MN) | Microplate reader (Bio-Tek Elx 800) | VEGF,VEGFR-1,VEGFR-2,bFGF,ICAM,PlGF, E-selection |
0,every 6week | IIIB-IV /NSCLC |
Chemotherapy |
| [85]Nan Du | Chinese | 72 | Protective Randomized |
ELSIA(USCN) | Microplate reader(Bio-Rad, model 550) | VEGF, CEA | 0, 3cycle | III-IV /NSCLC |
Chemotherapy |
| [74]Eleftherios Dalaveris | Greek | 30 | Protective | ELSIA(R&D Systems Minneapolis, MN) | Lower Limited detection 0.9pg/ml |
VEGF, TNF-γ, 8-ISO | 0(Pretreatment) | NSCLC | diagnosis |
| [94]Nikoletta Rovina | Greek | 76 | Protective | ELSIA(R&D Systems Minneapolis, MN, USA) | Lower Limited detection 20.0pg/ml |
VEGF, IL-18 |
0(Pretreatment) | NSCLC/ SCLC |
diagnosis |